All the while FDA is assessing their application, this peer reveiewed selection and presentation gives them more credibility and opporunitty to explain the progress made since their last submission.
As well as an opporunity to share the 4 years data to reach further with awareness...and probably support(direct or indirect).
Ann: Remestemcel Clinical and Potency Studies Presented at Tandem, page-9
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.39 |
Change
0.110(4.82%) |
Mkt cap ! $3.059B | |||
| Open | High | Low | Value | Volume |
| $2.31 | $2.43 | $2.30 | $15.10M | 6.360M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 9186 | $2.38 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.40 | 22000 | 3 |
View Market Depth
| Last trade - 16.11pm 23/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |